Artículos de revistas
Body Composition, Resting Energy Expenditure And Inflammatory Markers: Impact In Users Of Depot Medroxyprogesterone Acetate After 12 Months Follow-up
Registro en:
Archives Of Endocrinology And Metabolism. Sbem-soc Brasil Endocrinologia & Metabologia, v. 61, p. 70 - 75, 2017.
2359-3997
2359-4292
WOS:000395804800011
10.1590/2359-3997000000202
Autor
Batista
Gisele Almeida; de Souza
Aglecio Luiz; Marin
Daniela Miguel; Sider
Marina; Melhado
Vaneska Carvalho; Fernandes
Arlete Maria; Alegre
Sarah Monte
Institución
Resumen
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) The aim of this study was to evaluate for 12 months the changes of body weight using Depot Medroxyprogesterone Acetate (DMPA) and if these changes are related to inflammatory markers. Subjects and methods: Twenty women of childbearing age who chose the DMPA, without previous use of this method, BMI < 30 kg/m(2), and 17 women using IUD TCu 380A, participated in the study. At the baseline and after one year, changes in weight gain, body composition by the bioimpedance electric method, resting energy expenditure (REE) by the indirect calorimetry method, inflammatory markers and HOMA-IR were assessed. Results: After 12 months of evaluation, we could observe a significant increase in the DMPA group in weight (3,01 kg) and BMI, while the IUD group's only significant increase was observed in the BMI. Relative to REE there was an increase of basal metabolic rate (BMR) in both groups after one year. The sub-group DMPA that gained < 3 kg had increased significant weight, BMI and body surface (BS) with respiratory quotient (RQ) reduction, while the sub-group that gained >= 3 kg had a significant increase in weight, BMI, BS, fat-free mass, fat mass, BMR, Leptin, HOMA-IR and waist circumference, with RQ significantly reduced. Conclusion: Our study found significant changes in weight, body composition and metabolic profile of the population studied in the first 12 months of contraceptive use. These changes mainly increased body weight, leptin levels and HOMA-IR which can contribute to the development of some chronic complications, including obesity, insulin resistance and diabetes mellitus. 61 1 70 75 Fapesp Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)